182 related articles for article (PubMed ID: 24145339)
21. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
22. Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.
Shao MS; Wong AT; Schwartz D; Weiner JP; Schreiber D
Ann Thorac Surg; 2016 Jun; 101(6):2148-54. PubMed ID: 27016842
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
[TBL] [Abstract][Full Text] [Related]
24. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
25. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road.
Depypere L; Lerut T; Moons J; Coosemans W; Decker G; Van Veer H; De Leyn P; Nafteux P
Dis Esophagus; 2017 Jan; 30(1):1-8. PubMed ID: 27704661
[TBL] [Abstract][Full Text] [Related]
26. [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)].
Schmidt T; Sisic L; Sterzing F; Haag GM; Kunzmann R; Grenacher L; Weichert W; Jäger D; Büchler MW; Ott K
Chirurg; 2015 Oct; 86(10):955-62. PubMed ID: 25715974
[TBL] [Abstract][Full Text] [Related]
27. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
28. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma.
Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim HW; Natori A; Chan BA; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW; Elimova E
Cancer Med; 2020 May; 9(9):3023-3032. PubMed ID: 32130793
[TBL] [Abstract][Full Text] [Related]
29. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma.
Murphy CC; Correa AM; Ajani JA; Komaki RU; Welsh JW; Swisher SG; Hofstetter WL
J Gastrointest Surg; 2013 Aug; 17(8):1359-69. PubMed ID: 23715646
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
[TBL] [Abstract][Full Text] [Related]
31. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
[TBL] [Abstract][Full Text] [Related]
33. Postchemoradiation resected locally advanced esophageal and gastroesophageal junction carcinoma: long-term outcome with or without intraoperative radiotherapy.
Calvo FA; Sole CV; Obregón R; Gómez-Espí M; Lozano MA; Gonzalez-Bayon L; García-Sabrido JL
Ann Surg Oncol; 2013 Jun; 20(6):1962-9. PubMed ID: 23254690
[TBL] [Abstract][Full Text] [Related]
34. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
[TBL] [Abstract][Full Text] [Related]
35. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma.
Shiozaki H; Slack R; Sudo K; Elimova E; Wadhwa R; Chen HC; Skinner HD; Komaki R; Lee JH; Weston B; Bhutani MS; Blum MA; Rogers JE; Maru DM; Hofstetter WL; Ajani JA
Oncology; 2015; 88(6):332-6. PubMed ID: 25765098
[TBL] [Abstract][Full Text] [Related]
36. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins.
Harvin JA; Lahat G; Correa AM; Lee J; Maru D; Ajani J; Marom EM; Welsh J; Bhutani MS; Walsh G; Roth J; Mehran R; Vaporciyan A; Rice D; Swisher S; Hofstetter W
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):412-20. PubMed ID: 22172216
[TBL] [Abstract][Full Text] [Related]
38. Assessing failure patterns of radical intent radiation strategies in patients with locally advanced carcinoma of the esophagus.
Mishra S; Ahmad F; Singh S; Singh RK; Das KJM; Kumar S
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1332. PubMed ID: 33369258
[TBL] [Abstract][Full Text] [Related]
39. Patterns of surveillance following curative intent therapy for gastroesophageal cancer.
Peixoto RD; Lim HJ; Kim H; Abdullah A; Cheung WY
J Gastrointest Cancer; 2014 Sep; 45(3):325-33. PubMed ID: 24756830
[TBL] [Abstract][Full Text] [Related]
40. Incidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain.
Nobel TB; Dave N; Eljalby M; Xing X; Barbetta A; Hsu M; Tan KS; Janjigian Y; Bains MS; Sihag S; Jones DR; Molena D
Ann Thorac Surg; 2020 Feb; 109(2):329-336. PubMed ID: 31614136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
